91484
document
Comparative dose efficacy study of atorvastatin versus simvastatin , pravastatin , lovastatin , and fluvastatin in patients with hypercholesterolemia ( the CURVES study ) The objective of this multicenter , randomized , open-label , parallel-group , 8-week study was to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitor atorvastatin 10 , 20 , 40 , and 80 mg compared with simvastatin 10 , 20 , and 40 mg , pravastatin 10 , 20 , and 40 mg , lovastatin 20 , 40 , and 80 mg , and fluvastatin 20 and 40 mg. Investigators enrolled 534 hypercholesterolemic patients ( low-density lipoprotein [ LDL ] cholesterol > or = 160 mg/dl [ 4.2 mmol/L ] and triglycerides < or = 400 mg/dl [ 4.5 mmol/L ] ) . The efficacy end points were mean percent change in plasma LDL cholesterol ( primary ) , total cholesterol , triglycerides , and high-density lipoprotein cholesterol concentrations from baseline to the end of treatment ( week 8 ) . Atorvastatin 10 , 20 , and 40 mg produced greater ( p < or = 0.01 ) reductions in LDL cholesterol , -38 % , -46 % , and -51 % , respectively , than the milligram equivalent doses of simvastatin , pravastatin , lovastatin , and fluvastatin . Atorvastatin 10 mg produced LDL cholesterol reductions comparable to or greater than ( p < or = 0.02 ) simvastatin 10 , 20 , and 40 mg , pravastatin 10 , 20 , and 40 mg , lovastatin 20 and 40 mg , and fluvastatin 20 and 40 mg. Atorvastatin 10 , 20 , and 40 mg produced greater ( p < or = 0.01 ) reductions in total cholesterol than the milligram equivalent doses of simvastatin , pravastatin , lovastatin , and fluvastatin . All reductase inhibitors studied had similar tolerability . There were no incidences of persistent elevations in serum transaminases or myositis .
91485
Intervention_Pharmacological
atorvastatin
91486
Intervention_Pharmacological
simvastatin
91487
Intervention_Pharmacological
pravastatin
91488
Intervention_Pharmacological
lovastatin
91489
Intervention_Pharmacological
fluvastatin
91490
Intervention_Pharmacological
3-hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitor atorvastatin 10 , 20 , 40 , and 80 mg
91491
Intervention_Pharmacological
simvastatin 10 , 20 , and 40 mg
91492
Intervention_Pharmacological
pravastatin 10 , 20 , and 40 mg
91493
Intervention_Pharmacological
lovastatin 20 , 40 , and 80 mg
91494
Intervention_Pharmacological
fluvastatin 20 and 40 mg.
91495
Intervention_Pharmacological
Atorvastatin
91496
Intervention_Pharmacological
simvastatin
91497
Intervention_Pharmacological
pravastatin
91498
Intervention_Pharmacological
lovastatin
91499
Intervention_Pharmacological
fluvastatin
91500
Intervention_Pharmacological
Atorvastatin
91501
Intervention_Pharmacological
simvastatin
91502
Intervention_Pharmacological
pravastatin
91503
Intervention_Pharmacological
lovastatin
91504
Intervention_Pharmacological
fluvastatin
91505
Intervention_Pharmacological
Atorvastatin
91506
Intervention_Pharmacological
simvastatin
91507
Intervention_Pharmacological
pravastatin
91508
Intervention_Pharmacological
lovastatin
91509
Intervention_Pharmacological
fluvastatin
91510
Outcome_Other
efficacy
91511
Outcome_Physical
plasma LDL cholesterol ( primary ) , total cholesterol , triglycerides , and high-density lipoprotein cholesterol concentrations
91512
Outcome_Physical
LDL cholesterol
91513
Outcome_Physical
LDL cholesterol
91514
Outcome_Physical
total cholesterol
91515
Outcome_Mental
tolerability
91516
Outcome_Other
.
91517
Outcome_Adverse-effects
serum transaminases or myositis .
91518
Participant_Condition
patients with hypercholesterolemia
91519
Participant_Condition
multicenter
91520
Participant_Sample-size
534 hypercholesterolemic patients ( low-density lipoprotein [ LDL ] cholesterol > or = 160 mg/dl [ 4.2 mmol/L ] and triglycerides < or = 400 mg/dl [ 4.5 mmol/L ] )